Esomeprazol Ethypharm

Selected form

There is no image.

Esomeprazol

Method of action: Antiulcer, Drugs For Acid Related Disorders, Inhibiting H +, K + -Atp-Ase, Proton Pump Inhibitor

Treatment option: Gastroesophageal Reflux Disease, Duodenal Ulcer, Reflux, Reflux Esophagitis, Zollinger-Ellison Syndrome, Difficulty Swallowing, Helicobacter Pylori, Esophagitis, Peptic Ulcer

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Esomeprazol Ethypharm

What is Esomeprazol Ethypharm?

Esomeprazol Ethypharm is a medicinal product containing the active substance esomeprazole. It belongs to a group of medications known as proton pump inhibitors (PPIs). These medications work by reducing the amount of acid produced by the stomach.

Mechanism of Action

The active ingredient, esomeprazole, is the s-isomer of omeprazole. It targets the gastric acid pump, specifically the enzyme system known as H^+/K^+-ATPase located in the parietal cells of the stomach wall. By inhibiting this enzyme, the medication prevents the final stage of stomach acid production. This leads to a decrease in overall gastric acidity, which facilitates the healing of acid-related damage and provides relief from symptoms associated with excess acid.

Therapeutic Use

This medication is primarily used to manage conditions where reducing stomach acid is beneficial. This includes the treatment of various forms of gastroesophageal reflux disease (GERD) and the management of ulcers. It is also utilized in combination with specific antibiotics to address certain bacterial infections in the stomach that can lead to ulcers.

Pharmaceutical Form

Esomeprazol Ethypharm is typically formulated as gastro-resistant capsules. These capsules are designed to pass through the stomach and release the active medication in the intestine. This ensures that the esomeprazole is protected from being broken down by stomach acid before it can be absorbed into the bloodstream.

Regulatory References

EMA EPAR for Nexium Control (Esomeprazole)

What side effects are possible with Esomeprazol Ethypharm?

Official Safety Profile and Adverse Reactions

The safety profile of esomeprazole is formally defined by regulatory documents, classifying potential adverse reactions by frequency and the body system affected. These classifications reflect how government agencies organize and communicate the medicine's risk profile.

Frequency-Classified Adverse Effects

Adverse reactions are grouped by incidence based on clinical data and post-marketing reports:

Common: Reactions occurring in 1% or more of patients, typically involving headache and gastrointestinal symptoms such as diarrhea, abdominal pain, flatulence, and nausea.
Uncommon: Less frequent effects include sleep disturbances (insomnia), dizziness, rash, and peripheral swelling (edema).
Rare/Very Rare: These include serious hypersensitivity reactions, changes in blood cell counts (leukopenia/thrombocytopenia), aggression, and hepatitis.

Serious and Duration-Related Safety Concerns

The official labeling highlights several clinically significant, though less frequent, safety concerns:

Severe Adverse Reactions: These encompass life-threatening skin conditions such as Stevens-Johnson syndrome (SJS) and Acute Tubulointerstitial Nephritis (ATIN), an inflammation of the kidney.
Metabolic Risk: Use can be associated with Hypomagnesemia (low serum magnesium), often observed after at least three months of treatment, which may lead to serious complications such as arrhythmias.
Long-Term Exposure: The risk of bone fracture (hip, wrist, or spine) and Vitamin B-12 deficiency is documented as being associated with prolonged daily use, typically beyond one year or three years, respectively.

Population-Specific Notes and Restrictions

The safety profile includes specific constraints. The medicine is contraindicated for patients with known hypersensitivity to esomeprazole or substituted benzimidazoles. Caution is noted for use in patients with severe hepatic impairment, where a maximum recommended dose may apply. Symptomatic relief during use does not eliminate the possibility of underlying gastric malignancy, a safety point emphasized in regulatory documents.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documentation strictly defines the Esomeprazole overdose profile based on symptoms reported in clinical and post-marketing experience. Seeking immediate medical attention is required in any suspected overdose scenario, as professional supportive care is essential to manage the officially documented manifestations.

Overdose presentations observed in documented cases may include effects on the central nervous system, such as confusion and drowsiness. Gastrointestinal manifestations like nausea and vomiting are also listed. A key cardiovascular sign reported is a rapid heartbeat (tachycardia). Doses up to 2,400 mg have been officially documented in exposure reports.

Official Regulatory Finding	Status
Specific Antidote	No specific antidote is known for Esomeprazole.
Management Protocol	Treatment must be symptomatic and supportive.
Procedural Limitation	Dialysis is not expected to be effective in drug removal, as Esomeprazole is extensively protein-bound.

Because no specific antidote exists, the management strategy is focused entirely on providing supportive care to address the officially recognized clinical manifestations. This approach, as mandated by regulatory authorities, confirms that immediate medical evaluation is necessary to manage potential severe signs such as tachycardia.

Therapeutic Uses of Esomeprazol Ethypharm

What Esomeprazol Ethypharm Treats: Main Uses and Benefits

Esomeprazol is a medication used in the management of symptoms associated with conditions caused by excessive stomach acid. The primary therapeutic goal is acid-related symptom relief and the promotion of healing in affected areas.

This medicine is used to support the management of symptoms associated with gastroesophageal reflux disease (GERD), the maintenance of healed erosive esophagitis, duodenal and gastric ulcers (often in combination with antibiotics for H. pylori bacteria), and pathological hypersecretory conditions such as Zollinger-Ellison syndrome.

The approach of this medication is to assist in controlling the acidic environment of the stomach, which may help with irritation and discomfort in the upper digestive tract. Information is provided regarding approved uses.

Quick Facts: Therapeutic Domains

Relief for heartburn and acid reflux discomfort
Management of symptoms from GERD
Support for healing of acid-related ulcers
Aids in management of hypersecretory conditions

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Esomeprazol Ethypharm — Official Regulatory Information

Absolute Contraindications

Use of Esomeprazol Ethypharm is strictly contraindicated for patients with a known hypersensitivity to esomeprazole, any component of the formulation, or to other medicines in the substituted benzimidazole class. It must also not be used in patients receiving the antiviral drug nelfinavir.

Age-Related Eligibility

Adults (ge 18 years) are eligible for all approved uses.
Pediatric Use: Safety and effectiveness are established for children and adolescents from 1 year to 17 years of age for specific conditions. Use is also established for infants 1 month to less than 1 year for short-term treatment of erosive esophagitis. Use in infants younger than 1 month is not established.

Conditional and Restricted Use

Population/Condition	Regulatory Status
Severe Hepatic Impairment (Child-Pugh Class C)	Use is permitted, but the maximum daily dose must not exceed 20 mg (restricted use).
Severe Renal Impairment	Not recommended due to limited clinical experience and lack of established safety data in this group.
Pregnancy	Use is conditional, permitted only if clearly needed and the benefit outweighs the potential risk.
Lactation (Breastfeeding)	Regulators advise that a decision should be made to either discontinue the drug or discontinue breastfeeding.

What should I know about interactions with other medicines?

Esomeprazol Ethypharm can influence and be influenced by various other medications, herbal remedies, and supplements. Always inform your doctor or pharmacist of all products you are currently taking, including those obtained without a prescription.

Reduced Absorption of Other Medicines

Esomeprazole reduces stomach acid, which can decrease the absorption and effectiveness of medicines that rely on an acidic environment. Examples include certain antifungals (like ketoconazole and itraconazole) and some HIV medicines (like atazanavir and rilpivirine). Concomitant use with these drugs is generally discouraged or requires careful monitoring and potential dose adjustments.

Altered Metabolism of Esomeprazole and Other Medicines

Esomeprazole is processed by certain liver enzymes (CYP2C19), and other drugs can affect this process, or vice versa, leading to altered blood levels.

Interaction Type	Affected Medicine Examples	Potential Effect
Esomeprazole reduces effect	Clopidogrel (anti-platelet)	Reduced effectiveness, potentially increasing cardiovascular risk.
Esomeprazole increases effect	Warfarin, Cilostazol (blood thinners)	Increased drug concentration, raising the risk of side effects like bleeding.
Other medicines reduce Esomeprazole effect	Rifampicin (antibiotic), St. John's Wort (herbal supplement)	May make Esomeprazole less effective.

Other Important Interactions

Methotrexate (for cancer and autoimmune disease): Esomeprazole may increase the level of Methotrexate in the blood, which can lead to toxicity. Temporary discontinuation of esomeprazole may be necessary.
Digoxin (heart medicine) and Diuretics (water pills): Concomitant use may increase the risk of side effects, including low magnesium levels in the blood (Hypomagnesaemia).

Mechanism of Action

The Mechanism of Proton Pump Inhibition

Esomeprazole Ethypharm acts as a proton pump inhibitor (PPI) by selectively accumulating within the acidic secretory canaliculi of the gastric parietal cells. The low pH environment activates the compound, converting it into its active sulfenamide metabolite.

This active metabolite then targets the H^+/ K^+- ATPase enzyme system, commonly known as the gastric proton pump, which is responsible for the final stage of acid secretion. The metabolite forms a stable, covalent disulfide bond with specific cysteine residues on the enzyme. This irreversible modification leads to the non-competitive deactivation of the proton pump. The primary system-level physiological consequence is a dose-dependent, sustained suppression of gastric hydrogen ion ( H^+) secretion, thereby establishing and maintaining an elevated intragastric pH level, independent of typical acid pathway stimulators like histamine or gastrin.

Dosage and Administration Information

Official Administration Guidelines

Esomeprazole administration is governed by precise, label-based instructions across multiple forms and usage contexts. The medicine is primarily administered orally in strengths of 20 mg or 40 mg, available as delayed-release capsules or tablets. The intravenous (IV) route is also officially approved for scenarios where oral intake is not feasible or for critical inpatient management.

Timing and Dosage Regimens

A foundational instruction for oral use is the timing in relation to meals; the medicine should be taken at least one hour before eating to ensure proper absorption. To maintain the function of the drug’s specialized protective coating, the delayed-release capsules or tablets must always be swallowed whole and must not be crushed or chewed.

Dosing frequency is typically once daily for most short-term and maintenance regimens, though a twice-daily schedule (e.g., 40 mg twice daily) is specified for conditions like Zollinger-Ellison Syndrome (ZES) and components of H. pylori triple therapy. Usage duration ranges from short-term courses of 4 to 8 weeks (for healing erosive esophagitis) to long-term maintenance therapy.

Special Procedural Contexts

For certain groups, such as adults with severe hepatic impairment, the official oral dose may be limited to a maximum of 20 mg once daily. In the event of a missed dose, the instruction is to take it as soon as it is remembered unless it is near the time of the next scheduled dose, in which case the missed dose should be skipped to prevent taking a double amount.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Esomeprazol Ethypharm

The research base for esomeprazole is derived from clinical trials and reviews exploring outcomes related to conditions associated with acid reflux and production. This overview summarizes the findings and limitations described in authoritative scientific literature, focusing on what was observed in patient populations.

Evidence for Healing and Preventing Esophageal Damage

The research base exploring erosive esophagitis (EE) outcomes used short-term, randomized controlled trials (RCTs) and systematic reviews. These studies explored how outcomes related to the inner lining of the esophagus were measured in adults who had confirmed acid damage. The primary measurements focused on the rate at which the tissue achieved a measured mucosal healing outcome and changes in patient-reported physical discomfort.

For patients whose EE outcomes had been classified as healed, intermediate-term, placebo-controlled trials monitored relapse or recurrence outcomes. Findings described patterns where the rates of recurrence outcomes varied between the group studied and the control group. A limitation is that controlled studies tracking this outcome do not typically extend beyond 12 months, meaning long-term outcomes beyond that period are not fully established.

Studies on Symptomatic Relief and Acid Control

Esomeprazole was evaluated in short-term, randomized, placebo-controlled trials involving adults experiencing episodic symptom patterns related to symptomatic GERD and frequent heartburn. Studies reported patterns where the proportion of patients reporting symptom outcomes varied when compared to those receiving a placebo. Evidence remains limited for certain specific symptomatic groups, such as those with Non-Erosive Reflux Disease (NERD).

Evidence in Special Populations

Studies have explored outcomes related to different age groups, including research focused on adolescents and children. For certain pediatric groups, particularly infants (1 to 11 months), evidence is limited, and some studies were designed primarily as safety studies. In these young populations, findings related to symptom outcomes were mixed or showed limited differentiation from control groups.

Frequently Asked Questions (FAQ)

Common questions about Esomeprazol Ethypharm (FAQ)

Q: Does taking this medicine prevent absorption of all nutrients?

Regulatory documents indicate that Esomeprazol Ethypharm can reduce the absorption of vitamin B12 (cyanocobalamin) during prolonged use. This is because the medicine changes stomach acidity, which is required for normal B12 absorption. Regulatory information notes this effect may be relevant for certain patient populations, especially during long-term treatment.

Q: Can I stop taking this medication suddenly when I feel better?

According to the official product information, regulatory documents advise against suddenly discontinuing treatment with Esomeprazol Ethypharm, particularly after long-term use. Stopping abruptly may lead to the return of acid-related symptoms, sometimes referred to as 'rebound' acidity. The decision to stop treatment and the method for doing so should be based on a healthcare professional's guidance.

Q: What is the recommended period of use for this medicine?

The recommended period of use for Esomeprazol Ethypharm varies significantly depending on the condition being treated. For example, treating a duodenal ulcer may require a two-week course, while preventing relapse of reflux esophagitis can involve maintenance therapy. The official product information specifies different durations for various indications, ranging from short courses to ongoing treatment under supervision.

Q: What is the difference between Esomeprazol and Omeprazol?

Studies and official information indicate that Esomeprazol is the S-isomer of Omeprazol. This means they are very closely related in chemical structure and both belong to the class of medicines known as Proton Pump Inhibitors (PPIs). Esomeprazol is a specific compound that is chemically related to, and metabolized differently from, Omeprazol.

Q: Does Esomeprazol Ethypharm contain gluten or any animal derivatives?

The official product information lists the ingredients of Esomeprazol Ethypharm. It is specified that the medicine contains sucrose but no gluten. Information regarding specific animal derivatives is not highlighted in the primary regulatory patient documents, but the inactive ingredients list can be referenced for full details.

Q: Can I crush or open the capsules if I have trouble swallowing them?

According to official documentation, the capsules of Esomeprazol Ethypharm must not be chewed or crushed. The capsules contain special enteric-coated pellets. This coating is necessary to protect the medicine from degradation in the stomach. If swallowing the whole capsule is difficult, official instructions suggest opening it and mixing the pellets with a small amount of non-carbonated liquid or soft food, which must then be swallowed immediately.

How should Esomeprazol Ethypharm be stored and disposed of?

Storage and Disposal of Esomeprazol Ethypharm

The medicine must be stored at controlled room temperature, typically between 20^circ and 25 C (68^circ to 77 F), and below 30 C. The product should be stored in its original package to protect from moisture; for bottles, the container must be kept tightly closed.

Key Requirements

Condition Type	Requirement
Temperature	Store below 30 C. Do not freeze.
Child Safety	Keep out of the sight and reach of children.
Stability	Use capsules in bottles within 3 months after opening.

Disposal must follow specific environmental protocols: the medicine must not be thrown away via household waste or wastewater. Unused product and waste material should be discarded in accordance with local requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.